1-8 of 8
Chunxiao Wang
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed/refractory CLL: the phase 1b BRUIN trial

Clinical Trials & Observations
Lindsey E. Roeker, Jennifer A. Woyach, Chan Y. Cheah, Catherine C. Coombs, Nirav N. Shah, William G. Wierda, Manish R. Patel, Nicole Lamanna, Donald E. Tsai, Binoj Nair, Chunxiao Wang, Xiang Zhao, Dan Liu, David Radtke, Sonya Chapman, Narasimha Marella, Samuel C. McNeely, Jennifer R. Brown
Journal: Blood
Blood (2024) 144 (13): 1374–1386.
https://doi.org/10.1182/blood.2024024510
Published: 2024
Includes: Supplemental data
Journal Articles

Pirtobrutinib in Richter Transformation: Updated Efficacy and Safety Results with 18-Month Median Survival Follow-up from the Phase 1/2 BRUIN Study

William G. Wierda, Nirav N. Shah, Chan Yoon Cheah, David Lewis, Marc S. Hoffmann, Catherine C. Coombs, Nicole Lamanna, Shuo Ma, Deepa Jagadeesh, Talha Munir, Yucai Wang, Toby A. Eyre, Joanna M. Rhodes, Matthew McKinney, Ewa Lech-Maranda, Constantine S. Tam, Wojciech Jurczak, Koji Izutsu, Alvaro J. Alencar, Manish Patel, John F. Seymour, Jennifer A. Woyach, Lindsey E. Roeker, Philip A. Thompson, Paolo Abada, Caleb Ho, Narasimha Marella, Chunxiao Wang, Amy S. Ruppert, Binoj Chandrasekharan Nair, Hui Liu, Donald E. Tsai, Paolo Ghia
Journal: Blood
Blood (2023) 142 (Supplement 1): 1737.
https://doi.org/10.1182/blood-2023-181108
Published: 2023
Journal Articles

Fixed-Duration Pirtobrutinib Combined with Venetoclax ± Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia: Updated Results, Including MRD Data, from the BRUIN Phase 1b Study

Lindsey E. Roeker, Jennifer A. Woyach, Chan Y. Cheah, Catherine C Coombs, Nirav N. Shah, William G. Wierda, Manish Patel, Donald E. Tsai, Binoj Nair, Chunxiao Wang, Xiang Zhao, Narasimha Marella, Caleb Ho, Samuel McNeely, Jennifer R. Brown
Journal: Blood
Blood (2023) 142 (Supplement 1): 3269.
https://doi.org/10.1182/blood-2023-181090
Published: 2023
Journal Articles

Genomic Evolution and Resistance during Pirtobrutinib Therapy in Covalent BTK-Inhibitor (cBTKi) Pre-Treated Chronic Lymphocytic Leukemia Patients: Updated Analysis from the BRUIN Study

Jennifer R. Brown, Sai Prasad Desikan, Bastien Nguyen, Helen Won, Shady I. Tantawy, Samuel McNeely, Narasimha Marella, Kevin Ebata, Jennifer A. Woyach, Krish Patel, Constantine S. Tam, Toby A. Eyre, Chan Y. Cheah, Nirav N. Shah, Paolo Ghia, Wojciech Jurczak, Minna Balbas, Binoj Nair, Paolo Abada, Chunxiao Wang, Ying (Denise) Wang, Lindsey E. Roeker, Varsha Gandhi, William G. Wierda
Journal: Blood
Blood (2023) 142 (Supplement 1): 326.
https://doi.org/10.1182/blood-2023-180143
Published: 2023
Journal Articles

Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory CLL/SLL: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study

Anthony R. Mato, Jennifer A. Woyach, Jennifer R. Brown, Paolo Ghia, Krish Patel, Toby A. Eyre, Talha Munir, Ewa Lech-Marańda, Nicole Lamanna, Constantine S. Tam, John F. Seymour, Nirav N. Shah, Catherine C. Coombs, Chaitra S. Ujjani, Manish R. Patel, Bita Fakhri, Chan Y. Cheah, Alvaro J. Alencar, Jonathon B. Cohen, James N. Gerson, Ian W. Flinn, Shuo Ma, Deepa Jagadeesh, Joanna M. Rhodes, Francisco Hernandez-Ilizaliturri, Pier Luigi Zinzani, Minna Balbas, Binoj Nair, Paolo B. Abada, Chunxiao Wang, Denise Wang, Donald E. Tsai, William G. Wierda, Wojciech Jurczak
Journal: Blood
Blood (2022) 140 (Supplement 1): 2316–2320.
https://doi.org/10.1182/blood-2022-159497
Published: 2022
Journal Articles

Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory Mantle Cell Lymphoma: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study

Michael L. Wang, Nirav N. Shah, Wojciech Jurczak, Pier Luigi Zinzani, Toby A. Eyre, Chan Y. Cheah, Chaitra S. Ujjani, Youngil Koh, Koji Izutsu, James N. Gerson, Ian W. Flinn, Benoit Tessoulin, Alvaro J. Alencar, Shuo Ma, Ewa Lech-Marańda, Joanna M. Rhodes, Krish Patel, Jennifer A. Woyach, Nicole Lamanna, Yucai Wang, Constantine S. Tam, John F. Seymour, Talha Munir, Hirokazu Nagai, Francisco Hernandez-Ilizaliturri, Anita Kumar, Andrew D. Zelenetz, Preetesh Jain, Binoj Nair, Donald E. Tsai, Minna Balbas, Richard A. Walgren, Paolo B. Abada, Chunxiao Wang, Junjie Zhao, Anthony R. Mato
Journal: Blood
Blood (2022) 140 (Supplement 1): 9368–9372.
https://doi.org/10.1182/blood-2022-159425
Published: 2022
Journal Articles

Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Richter Transformation: Results from the Phase 1/2 BRUIN Study

William G. Wierda, David John Lewis, Paolo Ghia, Nirav N. Shah, Catherine C. Coombs, Chan Y. Cheah, Nicole Lamanna, Joanna M. Rhodes, Marc Hoffmann, Shuo Ma, Toby A. Eyre, Talha Munir, Manish R. Patel, Alvaro J. Alencar, Constantine S. Tam, John F. Seymour, Wojciech Jurczak, Ewa Lech-Marańda, Lindsey E. Roeker, Philip A. Thompson, Paolo B. Abada, Chunxiao Wang, Binoj Nair, Hui Liu, Donald E. Tsai, Anthony R. Mato
Journal: Blood
Blood (2022) 140 (Supplement 1): 846–849.
https://doi.org/10.1182/blood-2022-157058
Published: 2022
Journal Articles

BRUIN CLL-313: A Phase 3 Open-Label, Randomized Study of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Trial in Progress)

Wojciech Jurczak, Caroline Dartigeas, Marta Coscia, Peter S. Ganly, Ghassan Al-Jazayrly, Chunxiao Wang, Katherine Bao, Ching Ching Leow, Safi Shahda, Pier Luigi Zinzani
Journal: Blood
Blood (2021) 138 (Supplement 1): 3732.
https://doi.org/10.1182/blood-2021-145938
Published: 2021